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Abstract 
Background: Infections caused by Acinetobacter baumannii are difficult to cure due to the acquisition of resistance 
by these bacteria and lead to an increase in the general costs of hospitalization. The aim of this study was to determine 
tigecycline susceptibility of Acinetobacter baumannii strains isolated from intensive care unit and non-intensive care 
unit patients with skin and soft tissue infections. 
Methods: MICs were tested by Etest among 70 Acinetobacter baumannii isolates. 
Results: The MIC range was from 0.5 to 8.0 mg L-1. For ESBL-producing Acinetobacter baumannii, as well as for strains 
without carbapenemases, the highest MIC to tigecycline value was 8.0 mg L-1. For AmpC-producing Acinetobacter 
baumannii, the highest MIC to tigecycline value was 6.0 mg L-1 and, for MBL-producing strains, 2.0 mg L-1. 
Conclusions: The majority of Acinetobacter baumannii strains isolated from ICU and non-ICU patients demonstrated 
high values of MIC range, MIC50 and MIC90 to tigecycline.
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Infections caused by Acinetobacter baumannii (A. bau-
mannii), a non-fermenting bacillus, represent 15.3% of all 
Gram-negative bacterial infections in Poland [1]. This kind 
of infection is difficult to cure due to the acquisition of re-
sistance by these bacteria, especially in intensive care units 
(ICUs). The development of bacterial resistance prolongs the 
time of treatment and raises mortality, and consequently, 
leads to an increase in the general costs of hospitalization 
[1, 2]. The application of tigecycline may be one of the 
therapeutic options available [3].
Tigecycline is the first commercially available broad-spec-
trum glycylcycline-class anitbiotic (active against bacteria 
with extended-spectrum b-lactamase substrate, plasmid-
mediated AmpC b-lactamase and metallo-b-lactamase). The 
bacteriostatic effect is achieved by reversibly binding to the 
30S ribosomal subunit. Glycylcyclines bind to ribosomes 
5-fold more potently than tetracycline and minocycline, 
which explains the better efficacy of this drug [3−5]. Tigecy-
cline was registered in the European Union in May 2006 for 
the treatment of complicated intra-abdominal infections 
(cIAIs) and complicated skin and skin structure infections 
(cSSSIs), except for diabetic foot infections in adults [3−5].
METHODS
The study was approved by the local Bioethical Com-
mittee (No. KBET/19/B /2013).
BACTERIAL ISOLATES
The study involved 70 strains of A. baumannii isolated 
from patients hospitalized in intensive care units (ICUs) and 
other surgical (non-ICU) departments in specialist hospitals 
in the Cracow area in the period 2009–2013. The clinical ma-
terials were surgical wound exudates — 54 samples; blood 
— 4 samples; peritoneal fluid — 7 samples, and surgical 
biopsy samples — 5 samples. Only one isolate per patient 
was accepted into the study.
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SPECIES IDENTIFICATION AND ANTIMICROBIAL 
SUSCEPTIBILITY TESTING
Species identification was carried out with API 20 NE 
strips (bioMérieux, Warsaw, Poland) according to manufac-
turer's instructions.
Susceptibility to tigecycline was evaluated by Etest 
(bioMérieux, Warsaw, Poland) according to manufacturer's 
instructions on freshly prepared Mueller Hinton II Agar (Bec-
ton Dickinson, Warsaw, Poland). The plates were inoculated 
with a 0.5 McF bacterial suspension. The culture plates were 
incubated in ambient air at 35 ± 1° C for 18–20 h. Escherichia 
coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 
strains were used as quality control samples. 
The results were expressed as MIC range, MIC50 and 
MIC90 values in mg L
-1 units. 
EVALUATION OF RESISTANCE MECHANISMS
The presence of ESBL and AmpC phenotypes in the ex-
amined isolates were identified by double-disk susceptibility 
test (DDST) with ceftazidime (Oxoid, England, distributed by 
Argenta, Poznań, Poland) and cefotaxime (Oxoid) as indica-
tors, and amoxicillin (Oxoid) and clavulanic acid (Oxoid) as 
inhibitors of ESBL. The MBL mechanism of resistance was 
detected by DDST with an EDTA disk, a disk containing 
a metallo-β-lactamase inhibitor and disks of ceftazidime 
(Oxoid) and imipenem (Oxoid), in accordance with the rec-
ommendations of the Polish National Reference Center 
for Antimicrobial Susceptibility Affairs (KORLD) based on 
EUCAST guidelines [6].
STATISTICAL ANALYSIS
Statistical analysis was performed using R Language 
and Environment for Statistical Computing software [7]. 
A P value of ≤0.05 was considered to be significant. 
RESULTS
Tigecycline MICs for Acinetobacter ranged from 
0.5 to 8.0 mg L-1. For ESBL-producing A. baumannii and 
for strains without carbapenemases, the highest MIC to 
tigecycline value was 8.0 mg L-1. For AmpC-producing 
A. baumannii, the highest MIC to tigecycline value was 
6.0 mg L-1, and for MBL-producing strains, 2.0 mg L-1. Detailed 
results are shown in Tables 1 and 2, as well as Figures 1−3.
DISCUSSION 
Since EUCAST has not determined in vitro breakpoints 
for susceptibility to tigecycline in relation to A. baumannii, 
conclusions should not be formally drawn as regards its 
sensitivity. Therefore, we compared the obtained MIC val-
ues with the distribution given by EUCAST [8, 9]. All strains 
that had MIC values ≤ 1 mg L-1 were considered sensitive 
to tigecycline and all strains that had MIC ≥ 2 mg L-1 were 
deemed insensitive (resistant) [10]. EUCAST recognizes that 
all strains with MIC ≤ 1 mg L-1 do not have mutations that 
can lead to the acquisition of resistance (apart from a natu-
ral and known resistance characteristic for a given species 
— determined by the EUCAST ECOFF value is as 1 mg L-1). 
However, Piewngam and Kiratisin [11] suggest that the MIC 
breakpoint should be modified to S ≤ 0.5 and R > 2 mg L-1. 
Table 1. Comparison of in vitro activity of tigecycline against A. baumannii strains. MIC values are given in mg L-1
A. baumannii MIC range MIC50 MIC90 % sensitive strains * % resistant strains *
All strains 0.5–8.0 3.0 6.0 NA/7.14 NA/80
Without carbapenemases 0.5–8.0 3.0 3.0 NA/23.80 NA/52.40
ESBL 2.0–8.0 4.0 6.0 NA/0 NA/94.73
AmpC 1.5–6.0 4.0 6.0 NA/0 NA/93.10
MBL 2.0  – – NA/0 NA/0
MIC — minimum inhibitory concentration; MIC50/90 — MICs at which 50% and 90% of the isolates were inhibited, respectively; NA — breakpoints for A. baumannii not 
available from EUCAST; * EUCAST breakpoints for Enterobacteriaceae family
Table 2. Comparison of tigecycline activity against A. baumannii from ICU and non-ICU strains. MIC values are given in mg L-1
Department No. of strains MIC range P-value MIC50 MIC90
ICU 36 0.5– 8.0 0.351 3.0 4.0
non-ICU 34 1.0–6.0 0.351 3.0 6.0
MIC — minimum inhibitory concentration; MIC50/90 — MICs at which 50% and 90% of the isolates were inhibited, respectively
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It has been pointed out that the determination of the an-
timicrobial activity of tigecycline might vary with the use 
of different methods, while the disk diffusion method is 
not reliable as regards the determination of susceptibility 
to tigecycline and gives lower susceptibility rates as com-
pared to Etest or the broth microdilution method (BMD) 
[10, 12]. Zarkotou et al. [13] compared the broth microdilu-
tion method with VITEK2, Etest and MIC test strips. They 
found that Etest produced susceptibility results similar to 
those obtained with broth microdilution, while MIC values 
obtained by VITEK2 were higher than in the case of other 
tests. Moreover, a good concordance of the disk diffusion, 
Etest and BMD methods was found by Piewngam and Ki-
ratisin [11].
On the other hand, there are some publications which 
present the opposite conclusions. Draghi et al. compared 
the results obtained by Etest in local laboratories with cen-
tralized broth dilution methods and found that MICs differ 
greatly between these methods. Therefore, for 219 strains, 
MIC for broth microdilution was at a lower (range 0.03−4 mg 
L-1, MIC50 = 0.25 mg L
-1, MIC90 = 1 mg L
-1) than for Etest (range 
0.03-16 mg L-1, MIC50 = 2 mg L
-1, MIC90 = 4 mg L
-1) [14]. In 
a more recent study, Tas et al. compared different methods 
for tigecycline MIC evaluation and found that the values dif-
fered between methods. Indeed, MIC50 = 2 mg L
-1, MIC90 = 4 
mg L-1 (0.1−8 mg L-1) for microdilution and MIC50 = 2 mg L
-1 
MIC90 = 6 mg L
-1 (0.1−12 mg L-1) for Etest are very similar to 
the results obtained in our study [12, 14]. As shown above, 
there is a great problem with obtaining reliable results of 
Acinetobacter susceptibility testing to tigecycline as there 
are no standardized guidelines, while the results from many 
studies have been inconclusive.
In our study, we used Etest because we believe that if 
this test is prepared with proper care on freshly prapared 
medium and a proper inoculum density, it produces re-
liable results when correlated with the microdilution 
method.
Tigecycline MICs for Acinetobacter varied from 0.5 to 8.0 
mg L-1 in our study. Moreover, 7.1% of the tested isolates 
were characterized by MIC values lower than or equal to 
ECOFF values and for 90% of isolates the the MIC value was 
≥ 2 mg L-1 (the MIC50 and MIC90 values were 3 and 6 mg 
L-1, respectively). Similar results indicating the presence of 
Acinetobacter strains with high MIC values were obtained 
by Piewngam and Kiratisin in a study of 290 isolates includ-
ing MDR (multidrug resistant) strains from different clini-
cal specimens from patients hospitalized at the University 
Hospital in Bangkok (MIC range, MIC50, and MIC90 values 
were 0.5-8.0 mg L-1, 2.0 mg L-1, and 4.0 mg L-1, respectively) 
[11]. Navon-Venezia et al. [15] reported high tigecycline 
Figure 1. MIC distribution of wild type (data from EUCAST) and clinical (presented results) strains of A. baumannii
Figure 2. Comparison of MICs for A. baumannii collected from ICU 
and non-ICU patients showed as beanplots. Boxplots with distribution 
curves, susceptibility rates using the EUCAST breakpoints for Entero-
bacteriaceae: susceptible < 1 mg L-1 (dark grey), intermediate 1−2 mg 
L-1 (medium grey), resistant > 2 mg L-1 (light grey), black line — mean
169
Katarzyna Talaga et al., Susceptibility to tigecycline
resistance in multidrug-resistant A. baumannii in a Tel Aviv 
hospital. They found that 54 of 82 (66%) of the MDR A. bau-
mannii isolates were resistant (MIC = 8 mg L-1 or higher), 10 
of 82 (12%) were intermediate (MIC 4–6 mg L-1) and only 
18 of 82 (22%) were susceptible to tigecycline. The MIC50 
and MIC90 values were 16 and 32 mg L
-1, respectively, with 
a wide range of 1.0–128 mg L-1 ]. These results are inconsist-
ent with some existing studies indicating the sensitivity of 
Acinetobacter to this drug. The results from the Resistance 
surveillance program report for selected European Nations 
(2011) which included Poland, showed that tigecycline and 
colistin had significant activity against Acinetobacter, mainly 
A. baumannii (86%). The MIC values were: MIC50 = 1 mg L
-1, 
MIC90 = 2 mg L
-1 (range from ≤ 0.03 to > 4) [16]. Moreover, 
Morfin-Otero and Dowzicky suggest that tigecycline’s in vitro 
efficacy against A. baumannii has remained more constant 
than that of the other antimicrobial agents, a view based on 
data in their study that tigecycline showed a small increase 
in MIC90 values from 1 mg L
-1 in 2004 through 2005 to 2 mg 
L-1 in 2006 through 2009 [17].
Treatment of complicated intra-abdominal and compli-
cated skin and soft tissue infections may contribute to the 
emergence and selection of multidrug-resistant bacterial 
strains in health care centres [18]. Although antibiotic resist-
ance occurs in various hospital wards and clinics, it is best 
documented in the ICU. In addition, there are indications 
that more resistant bacteria occur in these units than in 
other wards [19]. For most antimicrobial agents, resistance 
was considerably higher among A. baumannii isolates col-
lected from patients in ICUs than in non-ICU wards [5, 17]. We 
found that A. baumannii strains isolated from ICU patients 
have significantly higher MIC values for tigecycline (MIC50 = 
3.0 mg L-1, MIC90 = 4.0 mg L
-1) than Enterobacteriaceae strains 
isolated from the same wards (MIC50 = 1.5 mg L
-1; MIC90 = 
3.0 mg L-1; Wilcoxon test; P = 1.629e-09; W = 2495.5) (Data 
not shown). However, when we compared Acinetobacter 
strains isolated from ICU and non-ICU patients, we did not 
observe any differences (Wilcoxon test, P = 0.3508; W = 
535.5; Fig. 2, Table 2).
In our study, A. baumannii strains with a MDR pheno-
type producing ESBL and AmpC had MIC50 = 4.0 mg L
-1 
and MIC90 = 6.0 mg L
-1 and non-MDR MIC50/MIC90 = 3.0 mg 
L-1. Moreover, we found that strains without any resistant 
mechanisms for other drugs are seen on the distribution 
curve as a separate population with MICs below ECOFF, 
while strains with one or more mechanisms comprise another 
population (Fig. 3). That suggests that some of our strains, 
despite their nosocomial source, have wild type phenotypes. 
Eser et al. evaluated the MICs of MDR Acinetobacter and found 
that all strains had MICs lower than 2 µg mL-1 with MIC90 = 1.5 
µg mL-1 [19]. Morfin-Otero and Dowzicky (2012) found lower 
MIC values (MIC90 = 2 mg L
-1) in MDR strains than non-MDR 
strains (1 mg L-1) [17]. We checked whether isolates from 
sterile body sites (blood, peritoneal fluid, surgical biopsy 
samples) have a different susceptibility profile from strains 
from non-sterile body sites (wound exudates). Although we 
presumed that the former should display a sensitivity similar 
to the wild type, there was no difference observed between 
the strains (Wilcoxon test, p-value = 0.186; W = 523).
Our results suggest that the majority of A. baumannii 
strains isolated from ICU and non-ICU patients produce 
extended-spectrum beta-lactamases as ESBL or AmpC 
phenotype. Strains in our study were often collected from 
patients with chronic recurrent soft tissue and skin infections 
treated numerous times using various antimicrobial drugs, 
which favoured the selection of multi-resistant strains. 
The majority of A. baumannii strains isolated from ICU 
and non-ICU patients demonstrated high values of MIC 
Figure 3. Tigecycline MIC distributions of A. baumannii. Comparison of MICs for Acinetobacter producing ESBL, AmpC, and MBL with strains 
without carbapenemases (presented results) 
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range, MIC50 and MIC90 to tigecycline. These data sug gest 
that tigecycline cannot be an effective therapeutic option 
for the treatment of serious infections caused by A. bau-
mannii.
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